Research Areas

Papzimeos is the first FDA-approved therapy for recurrent respiratory papillomatosis, a rare HPV-driven disease that has long forced patients into repeated surgeries.

Activace platform enables targeted, genome-wide profiling of unmethylated DNA regions, providing a comprehensive view of the epigenome that can be scaled to the study of large patient cohorts

Advances in allosteric inhibitors may offer a new standard of care that balances potent disease control with better tolerability and convenience.

LGC Standards reveals new 13C-labelled PFAS mixtures and single solutions to support laboratories using EPA Method 1633.

A novel cannabis-based therapy shows promise as a safe, effective non-opioid alternative for chronic low back pain.

The HDAC inhibitor givinostat has received regulatory approval in the US, EU, and UK for patients six years and older.

Promising new therapies for Huntington’s disease and multiple myeloma, the first FDA approval for Barth syndrome, and more led the news this week. 

From vascularized organoids to Parkinson's disease in a dish, scientists are pushing the boundaries of 3D cell research.

Final results from the AMPLIFY-201 phase 1 trial highlight durable T cell responses and prolonged survival in patients with colorectal and pancreatic cancer.

Men have long lacked reversible contraceptives, but new hormonal and non-hormonal methods in development could finally give them control over family planning.